Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
P/E ratio for Alpine Immune Sciences, Inc. (ALPN)
P/E ratio as of 2023: -29.61
According to Alpine Immune Sciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -29.61. At the end of 2022 the company had a P/E ratio of -4.25.
P/E ratio history for Alpine Immune Sciences, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -29.61 |
| 2022 | -4.25 |
| 2021 | -7.01 |
| 2020 | -9.39 |
| 2019 | -1.66 |
| 2018 | -1.40 |
| 2017 | -9.33 |
| 2016 | -1.10 |
| 2015 | -3.18 |
| 2014 | -9.05 |
| 2013 | -8.40 |
| 2012 | -14.22 |